Patent intelligence · US
US 9700639
Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
Patent details — US 9700639
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 11, 2017
- Expiration
- Jul 6, 2037
- Applicant
- Aura Biosciences, Inc.
- Claims
- 24
- CPC classes
- A61K, A61K38/162, A61K45/06, A61K47/6901
Quick answer
US 9700639 (Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells) is held by Aura Biosciences, Inc.. Status: granted. Granted Jul 11, 2017. Expires Jul 6, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Aura Biosciences, Inc.
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61K, A61K38/162, A61K45/06, A61K47/6901, A61K47/6929, A61K49/0056
More from Aura Biosciences, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11786503
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
granted -
US 11166936
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
granted -
US 10874633
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
granted -
US 10806716
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
granted -
US 10688172
HPV particles and uses thereof
granted -
US 10596275
Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
granted -
US 10300150
Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
granted -
US 10179168
HPV particles and uses thereof
granted
Frequently asked questions
What is US patent 9700639?
US 9700639 (Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells) is held by Aura Biosciences, Inc.. Status: granted. Granted Jul 11, 2017. Expires Jul 6, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9700639?
Aura Biosciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 17 pharmaceutical patents for this assignee.
When does US 9700639 expire?
Our index shows an expiration date of Jul 6, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.